xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05999357</url>
    </required_header>
    <id_info>
      <org_study_id>CJDQ443B1NL01T</org_study_id>
      <secondary_id>2023-505721-13-00</secondary_id>
      <nct_id>NCT05999357</nct_id>
    </id_info>
    <brief_title>JDQ443 for KRAS G12C NSCLC Brain Metastases</brief_title>
    <acronym>STRIDER</acronym>
    <official_title>A Phase II Study evaluaTing intRacranial effIcacy of JDQ443 in patiEnts With KRAS G12C+ NSCLC and bRain Metastases</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Maastricht University Medical Center</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Novartis</agency>
        <agency_class>Industry</agency_class>
      </collaborator>
    </sponsors>
    <source>Maastricht University Medical Center</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The goal of this phase II clinical trial is to evaluate the intracranial efficacy of JDQ443,&#xD;
        a KRAS G12C inhibitor in patients with KRAS G12C+ NSCLC and brain metastases (cohort A:&#xD;
        asymptomatic, untreated brain metastases, cohort B: asymptomatic, treated brain metastases).&#xD;
        The main question it aims to answer is to evaluate the intracranial efficacy, according to&#xD;
        RANO-BM criteria, in patients with asymptomatic and untreated brain metastases.&#xD;
  &#xD;
        Participants will receive JDQ443 200 mg BID until unacceptable toxicity or disease&#xD;
        progression.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        In the past decade, the treatment and prognosis of patients with metastatic non-small cell&#xD;
        lung cancer (NSCLC) has significantly improved, due to new systemic treatments (i.e.&#xD;
        intravenous or oral therapy). NSCLC is increasingly subtyped based on the presence of certain&#xD;
        mutations in the NSCLC for which targeted therapies have become available. KRAS G12C is the&#xD;
        most commonly found mutation, and recently oral therapies (sotorasib in the EU and USA,&#xD;
        adagrasib in the USA) have become available.&#xD;
  &#xD;
        Brain metastasis (BM) incidence in patients with KRAS G12C+ non-small cell lung cancer&#xD;
        (NSCLC) is high, but unfortunately, except for one small trial with adagrasib, patients with&#xD;
        BM were excluded from most clinical trials with KRAS G12C inhibitors. Furthermore, sotorasib&#xD;
        is not very well able to reach the central nervous system (CNS). Adagrasib can penetrate into&#xD;
        the CNS, but this comes with relevant treatment related toxicity (mainly gastro-intestinal&#xD;
        and liver). JDQ443 is a new oral KRAS G12C inhibitor, that preclinically has the same ability&#xD;
        as adagrasib to reach the CNS, but based on small series seems to have less toxicity. As&#xD;
        toxicity seems favourable for JDQ443 compared with sotorasib and adagrasib, and as&#xD;
        preclinically, CNS penetration seems comparable to adagrasib, data regarding the efficacy of&#xD;
        JDQ443 on BM is urgently needed. Therefore the main objective of this trial is to evaluate&#xD;
        the intracranial efficacy of JDQ443 in patients with KRAS G12C+ NSCLC and asymptomatic&#xD;
        untreated BM. Furthermore, there will be an exploratory cohort for patients with asymptomatic&#xD;
        and treated BM.&#xD;
  &#xD;
        The intervention consists of JDQ443 200 mg BID until unacceptable toxicity or disease&#xD;
        progression.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">November 2023</start_date>
    <completion_date type="Anticipated">August 2028</completion_date>
    <primary_completion_date type="Anticipated">August 2027</primary_completion_date>
    <phase>Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <intervention_model_description>Single arm, open-label, 2-cohort phase II study. Cohort A: asymptomatic, untreated BM, Cohort B: asymptomatic, treated BM.</intervention_model_description>
      <primary_purpose>Treatment</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>brain metastases overall response rate (ORR)</measure>
      <time_frame>up to 24 months</time_frame>
      <description>ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) based on central and local investigator's assessment according to RANO-BM criteria on brain MRI</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>brain metastases disease controle rate (DCR) (key secondary)</measure>
      <time_frame>up to 24 months</time_frame>
      <description>DCR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Non-CR/Non-PD according to RANO-BM on brain MRI</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>CNS progression free survival (PFS) (key secondary)</measure>
      <time_frame>up to 24 months</time_frame>
      <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on local and central assessment according to RANO-BM on brain MRI</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Extracranial ORR and DCR</measure>
      <time_frame>up to 24 months</time_frame>
      <description>ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) based on local investigator's assessment, DCR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Non-CR/Non-PD according to RECIST 1.1, measured with CT</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>extracranial PFS</measure>
      <time_frame>up to 24 months</time_frame>
      <description>PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on local assessment according to RECIST 1.1 based on CT</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>overall PFS</measure>
      <time_frame>up to 24 months</time_frame>
      <description>median overall PFS based on RANO-BM for BM and RECIST 1.1 for extracranial lesions as defined above</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>overall survival</measure>
      <time_frame>up to 33 months</time_frame>
      <description>OS is defined as the time from date of start of treatment to date of death due to any cause</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change from baseline in EORTC QLQ-BN20</measure>
      <time_frame>up to 24 months</time_frame>
      <description>the EORTC QLQ-BN20 is a questionnaire available that measures health-related quality of life of brain tumour patients</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Change from baseline in EORTC QLQ-C30</measure>
      <time_frame>up to 24 months</time_frame>
      <description>The EORTC QLQ-C30 is a questionnaire developed to assess the health-related quality of life of cancer participants</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Safety according to CTCAE v5.0</measure>
      <time_frame>up to 24 months</time_frame>
      <description>according to CTCAE v5.0</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">42</enrollment>
    <condition>Non Small Cell Lung Cancer Metastatic</condition>
    <condition>Brain Metastases, Adult</condition>
    <condition>KRAS G12C</condition>
    <arm_group>
      <arm_group_label>adult patients with KRAS G12C+ NSCLC and brain metastases</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Cohort A: adult patients with KRAS G12C+ NSCLC and untreated asymptomatic BM Cohort B: Adult patients with KRAS G12C+ NSCLC and treated asymptomatic BM&#xD;
  JDQ443 200 mg BID until unacceptable toxicity or disease progression</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>JDQ443</intervention_name>
      <description>JDQ443 tablets, orally administered</description>
      <arm_group_label>adult patients with KRAS G12C+ NSCLC and brain metastases</arm_group_label>
      <other_name>no other name</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
          In order to be eligible to participate in this study, a subject must meet all of the&#xD;
          following criteria:&#xD;
  &#xD;
            1. Signed informed consent must be obtained prior to participation in the study.&#xD;
  &#xD;
            2. Participant is an adult ≥ 18 years of age at the time of informed consent.&#xD;
  &#xD;
            3. ECOG performance status ≤2.&#xD;
  &#xD;
            4. Estimated life expectancy of 12 weeks or more&#xD;
  &#xD;
            5. Metastatic (stage IV) NSCLC with the presence of a KRAS G12C mutation (local test,&#xD;
               tissue as well as liquid biopsy allowed) and untreated or progressing asymptomatic BM&#xD;
               (cohort A) or treated and stable BM (cohort B).&#xD;
  &#xD;
            6. BM not in eloquent area (all patients have at least to be discussed with a&#xD;
               neurologist, and preferably they are discussed in a neuro-oncology MDT). If treated&#xD;
               with radiotherapy and stable, these patients are eligible for cohort B.&#xD;
  &#xD;
            7. Max BM size 2 cm in longest diameter (for each BM) for cohort A&#xD;
  &#xD;
            8. For cohort A: at least one untreated brain metastasis ≥ 5mm:&#xD;
  &#xD;
                 1. Patients with largest measurable intracranial lesion ≥5 mm but &lt;10 mm may be&#xD;
                    allowed to enroll upon agreement with the principal investigator (for patients&#xD;
                    with target lesions of ≥ 5mm but &lt;10 mm, 1.5 mm slice thickness brain MRI is&#xD;
                    required).&#xD;
  &#xD;
                 2. Prior local treatment is permissible if completed at least 14 days prior to study&#xD;
                    enrollment and provided unequivocal progression in the lesion has since occurred&#xD;
                    or if new lesions have occurred.&#xD;
  &#xD;
                 3. For at least 7 days prior to first dose of JDQ443 in this study: Patient must be&#xD;
                    asymptomatic from CNS metastases and on a stable dose of corticosteroids, with a&#xD;
                    maximum of 4 mg dexamethasone/day. Anti-epileptic dose should also be stable for&#xD;
                    7 days.&#xD;
  &#xD;
            9. Participant must have recovered from all toxicities related to prior treatments to&#xD;
               grade ≤ 1 (CTCAE v 5.0). Exception to this criterion are alopecia and vitiligo of any&#xD;
               grades.&#xD;
  &#xD;
           10. Adequate organ function including the following laboratory values at the screening&#xD;
               visit:&#xD;
  &#xD;
                 -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (without growth factor support),&#xD;
  &#xD;
                 -  Platelets ≥ 100 x 109/L (without growth factor support),&#xD;
  &#xD;
                 -  Hemoglobin (Hgb) ≥ 6 mmol/l (= 9 g/dl) (7 days without transfusions or growth&#xD;
                    factor support),&#xD;
  &#xD;
                 -  Aspartate transaminase (AST) ≤ 3 x ULN,&#xD;
  &#xD;
                 -  Alanine transaminase (ALT) ≤ 3 x ULN,&#xD;
  &#xD;
                 -  Total bilirubin ≤ 1.5 ULN,&#xD;
  &#xD;
                 -  Serum lipase ≤ 1.5 x ULN,&#xD;
  &#xD;
                 -  Creatinine clearance ≥ 60 mL/min by calculation using Cockcroft-Gault formula or&#xD;
                    based on 24-hour urine sample assessment.&#xD;
  &#xD;
           11. Participant is capable of swallowing study medication and following instructions&#xD;
               regarding study treatment administration.&#xD;
  &#xD;
           12. Participant must be able to communicate with the Investigator and comply with the&#xD;
               requirements of the study procedures.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
          A potential subject who meets any of the following criteria will be excluded from&#xD;
          participation in this study:&#xD;
  &#xD;
            1. Leptomeningeal metastasis (based on MRI or CSF cytology, if strong suspicion despite&#xD;
               negative MRI, CSF analysis should be done)&#xD;
  &#xD;
            2. Previous treatment with KRAS G12C inhibitor except if ≥ 1 year has elapsed since last&#xD;
               dose&#xD;
  &#xD;
            3. Tumors harbouring other oncogenic drivers for which targeted therapy is available&#xD;
               (note: patients with KRAS G12C mutation as a resistance mechanism on for example EGFR&#xD;
               or ALK inhibitors are not eligible).&#xD;
  &#xD;
            4. History of severe hypersensitivity reaction to JDQ443 or its excipients.&#xD;
  &#xD;
            5. History of allogeneic bone marrow or solid organ transplant&#xD;
  &#xD;
            6. Participant has had major surgery (e.g., intra-thoracic, intra-abdominal or&#xD;
               intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered&#xD;
               from side effects of such procedure.&#xD;
  &#xD;
            7. Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting the study treatment&#xD;
               or participants who have not recovered from radiotherapy-related toxicities. For all&#xD;
               other anatomic sites (including radiotherapy to thoracic vertebrae and ribs)&#xD;
               radiotherapy ≤ 2 weeks prior to starting the study treatment or has not recovered from&#xD;
               radiotherapy-related toxicities. Palliative radiotherapy for bone lesions ≤ 2 weeks&#xD;
               prior to starting study treatment is allowed.&#xD;
  &#xD;
            8. Clinically significant, uncontrolled cardiac disease and/or recent cardiac events&#xD;
               (within 6 months), such as:&#xD;
  &#xD;
                 -  Unstable angina or myocardial infarction within 6 months prior to screening.&#xD;
  &#xD;
                 -  Symptomatic congestive heart failure (defined as New York Heart Association Grade&#xD;
                    II or greater).&#xD;
  &#xD;
                 -  Documented cardiomyopathy.&#xD;
  &#xD;
                 -  Clinically significant cardiac arrhythmias (e.g. sustained ventricular&#xD;
                    tachycardia, and clinically significant second or third degree AV block without a&#xD;
                    pacemaker)&#xD;
  &#xD;
                 -  Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 160 mm Hg&#xD;
                    and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, unless controlled prior to&#xD;
                    first dose of study treatment.&#xD;
  &#xD;
                 -  History or current diagnosis of ECG abnormalities indicating significant risk of&#xD;
                    safety for study participation such as: concomitant clinically significant&#xD;
                    cardiac arrhythmias, e.g. sustained ventricular tachycardia, and clinically&#xD;
                    significant second or third degree AV block without a pacemaker.&#xD;
  &#xD;
                 -  History of familial long QT syndrome or known family history of Torsades de&#xD;
                    Pointes.&#xD;
  &#xD;
                 -  Resting QT interval corrected with Fridericia's formula (QTcF) &gt; 480 msec on&#xD;
                    screening ECG or congenital long QT syndrome.&#xD;
  &#xD;
                 -  Concomitant medication(s) with a &quot;Known Risk of Torsades de Pointe&quot; per&#xD;
                    www.qtdrugs.org that cannot be discontinued or replaced by safe alternative&#xD;
  &#xD;
            9. A medical condition that results in increased photosensitivity (i.e. solar urticaria,&#xD;
               lupus erythematosus, etc.).&#xD;
  &#xD;
           10. History of interstitial lung disease or pneumonitis grade ≥ 2.&#xD;
  &#xD;
           11. Current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (i.e.&#xD;
               uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or&#xD;
               hypercoagulability syndromes etc.).&#xD;
  &#xD;
           12. Malignant disease, other than that is being treated in this study. Exceptions to this&#xD;
               criterion include the following: malignancies that were treated curatively and have&#xD;
               not recurred within two years prior to study treatment; completely resected basal cell&#xD;
               and squamous cell skin cancers; any malignancy considered to be indolent and that has&#xD;
               never required therapy; and completely resected carcinoma in situ of any type.&#xD;
  &#xD;
           13. Any other concurrent severe and/or uncontrolled medical condition that would, in the&#xD;
               Investigator's judgment cause unacceptable safety risks, contra-indicate participation&#xD;
               in the clinical study or compromise compliance with the protocol (e.g. chronic&#xD;
               pancreatitis, uncontrolled diabetes, hepatic disorders including cirrhosis).&#xD;
  &#xD;
           14. Any other medical condition (such as active infection including known hepatitis or&#xD;
               HIV, treated or untreated), which in the opinion of the Investigator represents an&#xD;
               unacceptable risk for participation in the study.&#xD;
  &#xD;
           15. Any medical condition or prior surgical resection that may affect the absorption of&#xD;
               the investigational drug. Examples of medical conditions that may affect&#xD;
               investigational drug absorption include (but are not limited to) inflammatory bowel&#xD;
               disease (i.e. ulcerative colitis, Crohn's disease) and gastrointestinal disease such&#xD;
               as ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, and malabsorption&#xD;
               syndrome.&#xD;
  &#xD;
           16. Participants who are taking a prohibited medication (strong CYP3A inducers) that&#xD;
               cannot be discontinued at least seven days prior to the first dose of study treatment&#xD;
               and for the duration of the study.&#xD;
  &#xD;
           17. Use of any live vaccines against infectious diseases within four weeks of initiation&#xD;
               of study treatment.&#xD;
  &#xD;
           18. Participant is concurrently using other anti-cancer therapy.&#xD;
  &#xD;
           19. Participation in any additional, parallel, investigational drug or device studies.&#xD;
               Participation in non-interventional observational studies which will not influence the&#xD;
               endpoints of the current studies is allowed (e.g. liquid biopsies, eNOSE, surveys).&#xD;
  &#xD;
           20. Pregnant or breast-feeding women or women who plan to become pregnant or breast-feed&#xD;
               during the study. Pregnant women, where pregnancy is defined as the state of a female&#xD;
               after conception and until the termination of gestation, confirmed by a positive hCG&#xD;
               laboratory test.&#xD;
  &#xD;
           21. Women of child-bearing potential, defined as all women physiologically capable of&#xD;
               becoming pregnant, unless they are using highly effective methods of contraception&#xD;
               while taking study treatment and for 7 days after the last dose of JDQ443.&#xD;
  &#xD;
           22. Sexually active males unless they use a condom during intercourse while taking study&#xD;
               treatment and for 7 days after the last dose of JDQ443. Male participants should not&#xD;
               father a child in this period. A condom is required to be used also by vasectomized&#xD;
               men in order to prevent delivery of the study treatment via seminal fluid. In&#xD;
               addition, male participants must not donate sperm and women participants must not&#xD;
               donate oocytes for the time period specified above.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Lizza Hendriks, MD, PhD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Maastricht University Medical Hospital</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Lizza Hendriks, MD, PhD</last_name>
      <phone>+31(0)43-3875047</phone>
      <email>lizza.hendriks@mumc.nl</email>
    </overall_contact>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 2, 2023</study_first_submitted>
    <study_first_submitted_qc>August 11, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 21, 2023</study_first_posted>
    <last_update_submitted>August 11, 2023</last_update_submitted>
    <last_update_submitted_qc>August 11, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 21, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>non small cell lung cancer</keyword>
    <keyword>brain metastases</keyword>
    <keyword>KRAS G12C</keyword>
    <keyword>JDQ443</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
      <mesh_term>Neoplasm Metastasis</mesh_term>
      <mesh_term>Brain Neoplasms</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05999357
  org study id: CJDQ443B1NL01T
  secondary id: 2023-505721-13-00
  nct id: NCT05999357
  lead sponsor: 
  collaborator: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  The goal of this phase II clinical trial is to evaluate the intracranial efficacy of JDQ443,
        a KRAS G12C inhibitor in patients with KRAS G12C+ NSCLC and brain metastases (cohort A:
        asymptomatic, untreated brain metastases, cohort B: asymptomatic, treated brain metastases).
        The main question it aims to answer is to evaluate the intracranial efficacy, according to
        RANO-BM criteria, in patients with asymptomatic and untreated brain metastases.
  
        Participants will receive JDQ443 200 mg BID until unacceptable toxicity or disease
        progression.
  In the past decade, the treatment and prognosis of patients with metastatic non-small cell
        lung cancer (NSCLC) has significantly improved, due to new systemic treatments (i.e.
        intravenous or oral therapy). NSCLC is increasingly subtyped based on the presence of certain
        mutations in the NSCLC for which targeted therapies have become available. KRAS G12C is the
        most commonly found mutation, and recently oral therapies (sotorasib in the EU and USA,
        adagrasib in the USA) have become available.
  
        Brain metastasis (BM) incidence in patients with KRAS G12C+ non-small cell lung cancer
        (NSCLC) is high, but unfortunately, except for one small trial with adagrasib, patients with
        BM were excluded from most clinical trials with KRAS G12C inhibitors. Furthermore, sotorasib
        is not very well able to reach the central nervous system (CNS). Adagrasib can penetrate into
        the CNS, but this comes with relevant treatment related toxicity (mainly gastro-intestinal
        and liver). JDQ443 is a new oral KRAS G12C inhibitor, that preclinically has the same ability
        as adagrasib to reach the CNS, but based on small series seems to have less toxicity. As
        toxicity seems favourable for JDQ443 compared with sotorasib and adagrasib, and as
        preclinically, CNS penetration seems comparable to adagrasib, data regarding the efficacy of
        JDQ443 on BM is urgently needed. Therefore the main objective of this trial is to evaluate
        the intracranial efficacy of JDQ443 in patients with KRAS G12C+ NSCLC and asymptomatic
        untreated BM. Furthermore, there will be an exploratory cohort for patients with asymptomatic
        and treated BM.
  
        The intervention consists of JDQ443 200 mg BID until unacceptable toxicity or disease
        progression.
  allocation: N/A
  intervention model: Single Group Assignment
  intervention model description: Single arm, open-label, 2-cohort phase II study. Cohort A: asymptomatic, untreated BM, Cohort B: asymptomatic, treated BM.
  primary purpose: Treatment
  masking: None (Open Label)
  measure: brain metastases overall response rate (ORR)
  time frame: up to 24 months
  description: ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) based on central and local investigator's assessment according to RANO-BM criteria on brain MRI
  measure: brain metastases disease controle rate (DCR) (key secondary)
  time frame: up to 24 months
  description: DCR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Non-CR/Non-PD according to RANO-BM on brain MRI
  measure: CNS progression free survival (PFS) (key secondary)
  time frame: up to 24 months
  description: PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on local and central assessment according to RANO-BM on brain MRI
  measure: Extracranial ORR and DCR
  time frame: up to 24 months
  description: ORR is defined as the proportion of patients with best overall response of complete response (CR) or partial response (PR) based on local investigator's assessment, DCR is defined as the proportion of participants with Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Non-CR/Non-PD according to RECIST 1.1, measured with CT
  measure: extracranial PFS
  time frame: up to 24 months
  description: PFS is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on local assessment according to RECIST 1.1 based on CT
  measure: overall PFS
  time frame: up to 24 months
  description: median overall PFS based on RANO-BM for BM and RECIST 1.1 for extracranial lesions as defined above
  measure: overall survival
  time frame: up to 33 months
  description: OS is defined as the time from date of start of treatment to date of death due to any cause
  measure: Change from baseline in EORTC QLQ-BN20
  time frame: up to 24 months
  description: the EORTC QLQ-BN20 is a questionnaire available that measures health-related quality of life of brain tumour patients
  measure: Change from baseline in EORTC QLQ-C30
  time frame: up to 24 months
  description: The EORTC QLQ-C30 is a questionnaire developed to assess the health-related quality of life of cancer participants
  measure: Safety according to CTCAE v5.0
  time frame: up to 24 months
  description: according to CTCAE v5.0
  arm group label: adult patients with KRAS G12C+ NSCLC and brain metastases
  arm group type: Experimental
  description: Cohort A: adult patients with KRAS G12C+ NSCLC and untreated asymptomatic BM Cohort B: Adult patients with KRAS G12C+ NSCLC and treated asymptomatic BM
  JDQ443 200 mg BID until unacceptable toxicity or disease progression
  intervention type: Drug
  intervention name: JDQ443
  description: JDQ443 tablets, orally administered
  arm group label: adult patients with KRAS G12C+ NSCLC and brain metastases
  other name: no other name
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Lizza Hendriks, MD, PhD
  role: Principal Investigator
  affiliation: Maastricht University Medical Hospital
  last name: Lizza Hendriks, MD, PhD
  phone: +31(0)43-3875047
  email: lizza.hendriks@mumc.nl
  responsible party type: Sponsor
  mesh term: Carcinoma, Non-Small-Cell Lung
  mesh term: Neoplasm Metastasis
  mesh term: Brain Neoplasms
  sharing ipd: No